Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01371656 · ClinicalTrials.gov registry record · Phase 3

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

A Phase 3 study, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 3
Development phase
624
Enrollment target

NCT01371656 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 624 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01371656, a Phase 3 study, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
624 participants
Enrollment target

Study Summary

This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant. Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy or undergoing stem cell transplant for acute leukemia. It is not yet known whether levofloxacin is effective in preventing infection.

Interventions

  • DRUG levofloxacin

Trial Details

FieldValue
Enrollment Target 624 participants
Start Date 2011-09
Est. Completion 2017-06
Phase Phase 3

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT01371656

The ClinicalTrials.gov registry entry for NCT01371656 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which levofloxacin is the first listed.

NCT01371656 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01371656 about?

NCT01371656 is a clinical study titled "Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation". This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant. Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemothe...

What is the current status of trial NCT01371656?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2011-09. Estimated completion is 2017-06.

What interventions are being tested in trial NCT01371656?

The interventions under investigation include: levofloxacin (DRUG).

Who is sponsoring clinical trial NCT01371656?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.